Welcome to our dedicated page for Inogen news (Ticker: $INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inogen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inogen's position in the market.
Inogen, Inc. (Nasdaq: INGN) announced their first quarter 2024 financial results, showing an 8.1% increase in total revenue to $78.0 million, accompanied by a total gross margin of 44.1%. The GAAP net loss was $14.6 million, with adjusted net loss at $10.4 million. Adjusted EBITDA was a negative $7.6 million. Inogen expects revenue for the second quarter of 2024 to be in the range of $81 million to $84 million. The company remains focused on revenue growth, profitability, and innovation to enhance their market position.